EcoDrugPlus

Melanocortin 4 Receptor

Ensembl ID : ENSMZEG00005019514
Gene Symbol: MC4R
1 Cross references
89 Possible Orthologues:

Melanoma Receptor Tyrosine-Protein Kinase

Ensembl ID : ENSMZEG00005020342
Gene Symbol: LOC101477281
2 Cross references
215 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSMZEG00005007308
Gene Symbol: MTNR1A
3 Cross references
186 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSMZEG00005001703
Gene Symbol: MME
4 Cross references
233 Possible Orthologues:

Metabotropic Glutamate Receptor 2

Ensembl ID : ENSMZEG00005015414
Gene Symbol: LOC101472812
3 Cross references
206 Possible Orthologues:

Metabotropic Glutamate Receptor 3

Ensembl ID : ENSMZEG00005019934
Gene Symbol: LOC101468980
3 Cross references
215 Possible Orthologues:

Metabotropic Glutamate Receptor 5

Ensembl ID : ENSMZEG00005023681
Gene Symbol: LOC101475907
3 Cross references
213 Possible Orthologues:

Metabotropic Glutamate Receptor 5-Like

Ensembl ID : ENSMZEG00005024331
Gene Symbol: LOC101480374
3 Cross references
211 Possible Orthologues:

Methionine Aminopeptidase 2

Ensembl ID : ENSMZEG00005000627
Gene Symbol: LOC101485813
4 Cross references
220 Possible Orthologues:

Microtubule-Associated Protein Tau

Ensembl ID : ENSMZEG00005008879
Gene Symbol: LOC101463783
2 Cross references
205 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSMZEG00005020626
Gene Symbol: MAPK1
3 Cross references
209 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSMZEG00005008971
Gene Symbol: LOC101474234
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).